Clinical Focus Cenexel CIT (CITrials) is a specialized full-service CRO with expertise in Phase I-IV trials, particularly CNS and internal medicine, offering pediatric, first-in-human, single and multiple ascending dose, and drug-drug interaction studies, which can align with sponsors seeking comprehensive trial capabilities.

Regional Footprint Operating across three facilities in Southern California, Cenexel CIT presents a convenient regional partner for sponsors targeting US CNS and internal medicine trials, enabling faster site activation and potential patient recruitment within a dense healthcare market.

Growth Readiness With a mid-size team and revenue in the lower-to-mid million range, Cenexel CIT may be positioned to scale through strategic collaborations, add-on studies, or expanded service lines to capture more Phase I-IV work from mid-market and niche therapeutic sponsors.

Therapeutic Breadth Extensive psychiatric and CNS trial capabilities covering schizophrenia, bipolar, MDD, insomnia, PTSD, migraines, ADHD, Alzheimer’s-related conditions, obesity, diabetes, and sleep disorders indicate opportunities for multi-protocol studies or portfolio diversification with CNS-focused sponsors.

Competitive Positioning Compared to larger CROs, Cenexel CIT offers focused CNS and internal medicine expertise, potentially shorter cycle times and personalized service. This positioning can be leveraged to pursue mid-size sponsors and niche phase opportunities seeking attentive, domestic sites with strong CNS trial credentials.